BioVersys AG (SWX:BIOV)

Switzerland · Delayed Price · Currency is CHF

26.60

-0.80 (-2.92%)

At close: Jul 31, 2026

BioVersys AG Financials Overview

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	2.47	2.47	1.21	1.14
Revenue Growth	88.54%	103.46%	6.50%	-
Gross Profit	2.47	2.47	1.21	1.14
Operating Income	-19.96	-19.96	-18.72	-17.7
Net Income	-21.83	-21.83	-18.72	-18.3
Earnings Per Share	-3.89	-3.89	-5.62	-6.13
EPS Growth	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Investments	82.51	82.51	32.62	28.38
Total Debt	22.65	22.65	18.07	17.46
Net Cash (Debt)	59.86	59.86	14.55	10.91
Net Cash Growth	-17.61%	311.30%	33.34%	-
Net Cash Per Share	10.66	10.66	4.37	3.66

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Operating Cash Flow	-21.95	-21.95	-15.57	-11.66
Capital Expenditures	-0.22	-0.22	-0.04	-0.05
Free Cash Flow	-22.16	-22.16	-15.61	-11.7
Free Cash Flow Growth	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Gross Margin	100.00%	100.00%	100.00%	100.00%
Operating Margin	-808.87%	-808.87%	-1543.45%	-1553.73%
Pretax Margin	-883.87%	-883.87%	-1543.20%	-1606.76%
Profit Margin	-884.52%	-884.52%	-1543.20%	-1606.76%
FCF Margin	-897.97%	-897.97%	-1287.06%	-1027.57%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023
Period Ending	Aug '26 Aug 2, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
PS Ratio	49.05	57.82	-	-